BioTime to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 28th
October 22 2018 - 8:00AM
Business Wire
Abstract Selected to be Highlighted by the
American Academy of Ophthalmology Organization Committee
BioTime, Inc. (NYSE American: BTX), a clinical-stage
biotechnology company focused on degenerative diseases, announced
today that updated results from a Phase I/IIa study of its lead
product candidate, OpRegen®, a retinal pigment epithelium cell
transplant therapy currently in development for the treatment of
dry age-related macular degeneration (Dry-AMD), will be presented
at the 2018 American Academy of Ophthalmology Annual Meeting (AAO
2018), to be held at the McCormick Place Convention Center in
Chicago, Illinois, USA (October 27 – 30, 2018). The abstract
presentation, entitled, “P1/2a Study of Subretinally Transplanted
Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry-Form
AMD Patients,” will be presented as part of the OP02 Retina,
Vitreous Original Paper Session on Sunday, October 28th, 2018
between 10:30 AM - 12:30 PM EDT in room S405 by Eyal Banin, MD,
PhD, Professor of Ophthalmology, Director, Center for Retinal and
Macular Degenerations, Department of Ophthalmology at
Hadassah-Hebrew University Medical Center (abstract number PA014).
The abstract will provide updated data from patient cohorts 1
through 3 of the study as well as outline initial data from patient
cohort 4 and has been selected to be highlighted by the AAO 2018
organization committee.
About OpRegen®
OpRegen® is a retinal pigment epithelium transplant therapy in
Phase I/IIa development for the treatment of dry age-related
macular degeneration, the leading cause of adult blindness in the
developed world. There were no unexpected serious adverse events
reported to date. OpRegen® consists of a suspension of retinal
pigment epithelial (RPE) cells delivered subretinally as an
intraocular injection. RPE cells are essential components of the
back lining of the retina and function to help nourish the retina
including photoreceptors. OpRegen® has been granted Fast Track
designation from the U.S. Food and Drug Administration.
OpRegen® is a registered trademark of Cell Cure Neurosciences Ltd.,
a majority-owned subsidiary of BioTime, Inc.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused
on the development and commercialization of novel therapies for the
treatment of degenerative diseases. BioTime’s pipeline is based on
two platform technologies which encompass cell replacement and
cell/drug delivery. BioTime’s lead cell replacement product
candidate is OpRegen®, a retinal pigment epithelium transplant
therapy in Phase 2 development for the treatment of dry age-related
macular degeneration, the leading cause of blindness in the
developed world. BioTime’s lead cell delivery clinical program is
Renevia®, an investigational medical device being developed as an
alternative for whole adipose tissue transfer procedures.
BioTime also has significant equity holdings in two publicly
traded companies, Asterias Biotherapeutics, Inc. (NYSE
American: AST) and OncoCyte Corporation (NYSE
American: OCX), and a private company, AgeX Therapeutics,
Inc.
BioTime common stock is traded on the NYSE American and
TASE under the symbol BTX. For more information, please
visit www.biotime.com or connect with the company on
Twitter, LinkedIn, Facebook, YouTube, and Google+. To
receive ongoing BioTime corporate communications, please
click on the following link to join the Company’s email alert
list: http://news.biotime.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181022005270/en/
BioTime, Inc.Ioana C. Hone,
510-871-4188IR@biotimeinc.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jul 2023 to Jul 2024